New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2013
16:04 EDTALNYAlnylam commences offering of $125M of common shares
J.P. Morgan Securities and Morgan Stanley & Co. are acting as joint book-running managers and representatives of the underwriters for the offering.
News For ALNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 13, 2015
12:14 EDTALNYAlnylam maintains RNAi technology leadership, says Piper Jaffray
Subscribe for More Information
09:13 EDTALNYAlnylam expects to advance RNAi development candidates in 2016
In a presentation at the 11th Annual Meeting of the Oligonucleotide Therapeutics Society entitled "Reversirs for Rapid and Potent Reversal of siRNA Silencing Activity," Alnylam shared key scientific data characterizing the development of its Reversir platform. Reversir molecules are GalNAc-conjugated, single-stranded oligonucleotide constructs that are designed to recognize and bind to the complimentary RISC-bound antisense strand of an siRNA, leading to rapid and complete reversal of RNAi-mediated target gene silencing activity in vivo. Studies were performed in mice using a GalNAc-siRNA targeting Factor IX and Reversir constructs designed to specifically reverse the FIX siRNA silencing activity. Specifically, a single subcutaneous dose of the FIX siRNA led to robust FIX knockdown of approximately 80% that was sustained for over 4 weeks. When a single subcutaneous dose of the Reversir molecule was administered on day 8, FIX knockdown was rapidly reversed, with levels returning to baseline within one week. A preliminary rat toxicology study showed that Reversir constructs are generally well tolerated with no significant findings to date, including lack of changes in body weight gain or serum chemistry. Alnylam believes that its Reversir platform can be deployed across existing and future pipeline programs to enable tailored control of RNAi pharmacology for precision medicines, and expects to advance initial Development Candidates from this platform in 2016.
09:12 EDTALNYAlnylam sees advanced development candidate for Bis-RNAi in 2016
Subscribe for More Information
October 12, 2015
07:10 EDTALNYOligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
October 9, 2015
19:20 EDTALNYAlnylam management to meet with Leerink
Meetings to be held in Los Angeles on October 14 and in San Francisco on October 15 hosted by Leerink.
October 8, 2015
16:01 EDTALNYAlnylam initiates Phase 1 OLE study with ALN-AT3
Subscribe for More Information
October 1, 2015
13:00 EDTALNYAlnylam recent weakness a buying opportunity, says Piper Jaffray
Subscribe for More Information
07:01 EDTALNYGenzyme opts into ALN-AT3 Hemophilia Program
Subscribe for More Information
September 30, 2015
07:11 EDTALNYLeerink to hold a roundtable
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use